Neurocrine Biosciences, Inc. NBIX
165.31 USD -2.09 (-1.25%)
Regular-session close
157.34 -7.97 -4.82%
Pre-market · Nov 17, 4:01 AM ET
164.81 Day range 168.62
122.14 52-week range 186.12
- YTD
- +16.56%
- 1 year
- +15.15%
News
zacks.com Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.benzinga.com Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $191 Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $185 to $191.
zacks.com NBIX or GRDN: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX) and Guardian Pharmacy Services (GRDN). But which of these two stocks…
prnewswire.com Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference SAN DIEGO, Nov. 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the 2026 Jefferies Global Healthcare Conference in London…benzinga.com Neurocrine Biosciences Releases Findings From New Survey Showing Adults With Tardive Dyskinesia Reported Fewer Disruptions To Work, School After Starting Treatment With INGREZZA Capsules Survey reveals work or school disruptions among adults with tardive dyskinesia declined from 57% before treatment to 21% after starting INGREZZA, with average missed days per month decreasing from…
benzinga.com Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $224 Guggenheim analyst Delma Caiati maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $207 to $224.
benzinga.com Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $185 Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $183 to $185.
benzinga.com Nasdaq 100 Gets a Lift As Nvidia Overtakes Apple: Stock Market Today Apple's memory-cost margin warning hands Nvidia the top market value as chipmakers rebound. Here's what's happening in the stock market today.
benzinga.com Fabrinet, EverQuote, Lattice Semiconductor, Fiserv And Other Big Stocks Moving Higher On Tuesday U.S. stocks mixed as Dow fell 200 points; Fabrinet surged 13.7% on strong results, guidance and buyback, while several small caps rallied.benzinga.com RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $190 RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $187 to $190.
benzinga.com Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $220 Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $210 to $220.
benzinga.com Piper Sandler Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215 Piper Sandler analyst David Amsellem maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $210 to $215.
benzinga.com Neurocrine Biosciences Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B Neurocrine Biosciences (NASDAQ:NBIX) Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B
benzinga.com Neurocrine Biosciences Q3 Adj. EPS $3.29 Beats $1.91 Estimate, Sales $1.119B Beat $1.043B Estimate Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $3.29 per share which beat the analyst consensus estimate of $1.91 by 72.25 percent. This is a 51.61 percent increase over earnings…
benzinga.com Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott…benzinga.com Neurocrine Biosciences Identifies Clinically Meaningful Health Improvement Threshold For INGREZZA In Tardive Dyskinesia Patients New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with
benzinga.com Neurocrine Biosciences Announces Publication Of Expert Perspectives Highlighting Hyperphagia In Prader-Willi Syndrome As Neurobiologically Driven Condition Expert perspectives highlight the interaction of hypothalamic dysfunction, biological, behavioral, and environmental factors in shaping the challenges of hyperphagia in Prader-Willi syndrome for…
benzinga.com Neurocrine Biosciences Starts Phase 2 Clinical Trial Of NBI-1117567 To Treat Adults With Mild To Moderate Alzheimer's Disease Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1117567 (NBI-'567) in adults with mild to moderate Alzheimer's…
